We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Use Early Systems Approach to Minimize Design-Related Drug Errors
FDA: Use Early Systems Approach to Minimize Design-Related Drug Errors
January 2, 2013
Generic-drug makers should conduct risk assessments at the early stages of drug development and when changes or additions to an already marketed drug product occur to minimize design-related medication errors and avoid post-approval redesigns, according to a new FDA draft guidance.